[TITLE]MAAS Announces Strategic Expansion into Healthcare and Wellness with Acquisition of Carve Group Ltd:
[TEXT]
CHENGDU, China, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Maase Inc. (NASDAQ: MAAS) (“MAAS” or the “Company”) today announced the successful completion of its strategic acquisition of 100% equity interests in Carve Group Ltd (the “Target Company” or the “Carve Group”). The transaction, previously disclosed in the Company’s Form 6-K filed on July 29, 2025, was formally consummated on August 27, 2025.

Pursuant to the transaction agreement dated July 28, 2025, MAAS has acquired all equity interests in the Target Company from its existing shareholders, Golden Brighter Limited (“GBL”), WJ Management Company Limited (“WJM”), and Union Chief Limited (“UCL”) (collectively, the “Sellers”). As consideration, MAAS issued an aggregate of 195,894,609 Class A ordinary shares with a par value of US$0.09 per share (the “Consideration Shares”), at an issue price of US$1.50 per share. As of August 27, 2025 (the “Closing Date”), the Company had a total of 221,811,850 ordinary shares outstanding, consisting of 215,145,182 Class A ordinary shares and 6,666,668 Class B ordinary shares. The Sellers collectively hold 195,894,609 Class A ordinary shares of the Company, representing approximately 88.32% of the total issued share capital and approximately 22.22% of the total voting power. Among the Sellers, GBL and WJM each hold 93,049,939 shares, representing approximately 41.95% of the total issued share capital and approximately 10.55% of the total voting power, respectively. The shareholdings of GBL and WJM are subject to a five-year lock-up period. Following the acquisition, MAAS indirectly holds full ownership of Carve Group’s wholly-owned subsidiaries, Zhongshen Resources Development (Liaoning) Co., Ltd. (“Zhongshen”) and Glyken Bird Nest Technology (Shenzhen) Co., Ltd. (“Glyken”).

Zhongshen holds the land use rights for 111 mu of premium forest land in the core wild ginseng growing region of Hengren County, Liaoning Province, with over 19,000 scarce wild-grown ginseng roots aged over 40 years, establishing it as a provider of scarce upstream traditional Chinese medicine resource.

Glyken, owns the bird’s nest biotechnology factory in the Guangxi Free Trade Zone, it possesses an SC food production certification and an annual production capacity of 10 tons of bird’s nest peptides. Its product portfolio covers anti-aging, precision nutrition, functional food/beverages, and skincare, making it a benchmark in the bird’s nest biotech platform.

Leveraging Zhongshen’s scarce medicinal resources and Glyken’s biotechnology platform, MAAS will use modern biotechnology to scientifically upgrade traditional wellness products. This move establishes its presence in the healthcare and wellness space and underscores its commitment to building a globally competitive health product and service ecosystem.
[Source link]: https://www.globenewswire.com/news-release/2025/08/28/3140651/0/en/MAAS-Announces-Strategic-Expansion-into-Healthcare-and-Wellness-with-Acquisition-of-Carve-Group-Ltd.html


[TITLE]Kestra Advisory Services LLC Acquires 11,077 Shares of GE HealthCare Technologies Inc. $GEHC:
[TEXT]
Kestra Advisory Services LLC raised its holdings in GE HealthCare Technologies Inc. (NASDAQ:GEHC – Free Report) by 74.1% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 26,028 shares of the company’s stock after purchasing an additional 11,077 shares during the quarter. Kestra Advisory Services LLC’s holdings in GE HealthCare Technologies were worth $2,101,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently bought and sold shares of the business. Knuff & Co LLC grew its stake in GE HealthCare Technologies by 1.5% in the 1st quarter. Knuff & Co LLC now owns 10,276 shares of the company’s stock valued at $829,000 after purchasing an additional 150 shares during the period. Graypoint LLC grew its stake in GE HealthCare Technologies by 5.7% in the 1st quarter. Graypoint LLC now owns 3,028 shares of the company’s stock valued at $244,000 after purchasing an additional 162 shares during the period. Ferguson Wellman Capital Management Inc. grew its stake in GE HealthCare Technologies by 3.2% in the 1st quarter. Ferguson Wellman Capital Management Inc. now owns 5,336 shares of the company’s stock valued at $431,000 after purchasing an additional 166 shares during the period. Spire Wealth Management grew its stake in GE HealthCare Technologies by 5.2% in the 1st quarter. Spire Wealth Management now owns 3,367 shares of the company’s stock valued at $272,000 after purchasing an additional 166 shares during the period. Finally, Freestone Capital Holdings LLC lifted its position in shares of GE HealthCare Technologies by 5.1% during the 1st quarter. Freestone Capital Holdings LLC now owns 3,454 shares of the company’s stock valued at $279,000 after buying an additional 169 shares during the last quarter. Institutional investors own 82.06% of the company’s stock.

Get GE HealthCare Technologies alerts:

Analysts Set New Price Targets

A number of brokerages have recently commented on GEHC. BTIG Research reaffirmed a “buy” rating on shares of GE HealthCare Technologies in a research report on Monday, July 14th. UBS Group raised GE HealthCare Technologies from a “sell” rating to a “neutral” rating and dropped their price target for the company from $74.00 to $73.00 in a research report on Monday, May 5th. Citigroup upped their price target on GE HealthCare Technologies from $89.00 to $93.00 and gave the company a “buy” rating in a research report on Thursday, July 31st. Morgan Stanley dropped their price target on GE HealthCare Technologies from $78.00 to $74.00 and set an “equal weight” rating on the stock in a research report on Thursday, July 31st. Finally, Wall Street Zen raised GE HealthCare Technologies from a “hold” rating to a “buy” rating in a research report on Saturday, May 31st. Eight equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $88.55.

GE HealthCare Technologies Stock Performance

Shares of GEHC opened at $73.73 on Friday. The stock’s 50-day simple moving average is $74.23 and its 200 day simple moving average is $74.76. The stock has a market capitalization of $33.66 billion, a price-to-earnings ratio of 15.11, a price-to-earnings-growth ratio of 2.82 and a beta of 1.13. The company has a debt-to-equity ratio of 0.85, a quick ratio of 0.93 and a current ratio of 1.16. GE HealthCare Technologies Inc. has a 52-week low of $57.65 and a 52-week high of $94.80.

GE HealthCare Technologies (NASDAQ:GEHC – Get Free Report) last issued its quarterly earnings data on Wednesday, July 30th. The company reported $1.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.91 by $0.15. GE HealthCare Technologies had a return on equity of 23.93% and a net margin of 11.22%.The business had revenue of $5 billion for the quarter, compared to analysts’ expectations of $4.96 billion. During the same quarter in the prior year, the firm posted $1.00 EPS. The firm’s quarterly revenue was up 3.5% on a year-over-year basis. GE HealthCare Technologies has set its FY 2025 guidance at 4.430-4.630 EPS. Research analysts forecast that GE HealthCare Technologies Inc. will post 4.68 EPS for the current fiscal year.

GE HealthCare Technologies Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, August 15th. Shareholders of record on Friday, July 25th were issued a $0.035 dividend. The ex-dividend date of this dividend was Friday, July 25th. This represents a $0.14 annualized dividend and a dividend yield of 0.2%. GE HealthCare Technologies’s dividend payout ratio (DPR) is presently 2.87%.

GE HealthCare Technologies Profile

(Free Report)

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.

Further Reading

Want to see what other hedge funds are holding GEHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GE HealthCare Technologies Inc. (NASDAQ:GEHC – Free Report).

Receive News & Ratings for GE HealthCare Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GE HealthCare Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
[Source link]: https://www.etfdailynews.com/2025/08/30/kestra-advisory-services-llc-acquires-11077-shares-of-ge-healthcare-technologies-inc-gehc/


[TITLE]MetLife Investment Management LLC Decreases Stock Holdings in American Healthcare REIT, Inc. $AHR:
[TEXT]
MetLife Investment Management LLC trimmed its holdings in American Healthcare REIT, Inc. (NYSE:AHR – Free Report) by 1.6% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 94,449 shares of the company’s stock after selling 1,507 shares during the quarter. MetLife Investment Management LLC’s holdings in American Healthcare REIT were worth $2,862,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Wolff Wiese Magana LLC purchased a new stake in shares of American Healthcare REIT during the 1st quarter valued at approximately $25,000. MassMutual Private Wealth & Trust FSB raised its position in shares of American Healthcare REIT by 189.0% during the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 968 shares of the company’s stock valued at $29,000 after buying an additional 633 shares during the period. Spirit of America Management Corp NY purchased a new stake in shares of American Healthcare REIT during the 1st quarter valued at approximately $30,000. Avalon Trust Co purchased a new stake in shares of American Healthcare REIT during the 1st quarter valued at approximately $36,000. Finally, Continuum Advisory LLC purchased a new stake in shares of American Healthcare REIT during the 1st quarter valued at approximately $37,000. Hedge funds and other institutional investors own 16.68% of the company’s stock.

Get American Healthcare REIT alerts:

Insider Buying and Selling at American Healthcare REIT

In other news, CIO Stefan K.L. Oh sold 3,860 shares of the company’s stock in a transaction on Monday, June 30th. The stock was sold at an average price of $36.10, for a total transaction of $139,346.00. Following the sale, the executive owned 95,671 shares of the company’s stock, valued at approximately $3,453,723.10. This represents a 3.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 1.00% of the company’s stock.

American Healthcare REIT Stock Performance

NYSE:AHR opened at $42.79 on Monday. American Healthcare REIT, Inc. has a 52 week low of $20.15 and a 52 week high of $43.14. The company has a fifty day simple moving average of $38.75 and a two-hundred day simple moving average of $34.08. The company has a quick ratio of 0.48, a current ratio of 0.48 and a debt-to-equity ratio of 0.41. The company has a market cap of $7.21 billion, a price-to-earnings ratio of -194.48, a price-to-earnings-growth ratio of 2.19 and a beta of 1.09.

American Healthcare REIT (NYSE:AHR – Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported $0.42 earnings per share for the quarter, topping analysts’ consensus estimates of $0.40 by $0.02. American Healthcare REIT had a negative return on equity of 1.43% and a negative net margin of 1.56%.The business had revenue of $542.50 million for the quarter, compared to analyst estimates of $539.49 million. During the same quarter in the prior year, the company earned $0.33 earnings per share. The company’s revenue was up 7.5% on a year-over-year basis. American Healthcare REIT has set its FY 2025 guidance at 1.640-1.680 EPS. As a group, equities analysts anticipate that American Healthcare REIT, Inc. will post 1.41 earnings per share for the current fiscal year.

American Healthcare REIT Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, July 18th. Stockholders of record on Monday, June 30th were given a dividend of $0.25 per share. The ex-dividend date of this dividend was Monday, June 30th. This represents a $1.00 dividend on an annualized basis and a dividend yield of 2.3%. American Healthcare REIT’s dividend payout ratio is currently -454.55%.

Wall Street Analyst Weigh In

Several research firms have recently commented on AHR. Morgan Stanley lifted their price target on shares of American Healthcare REIT from $37.00 to $45.00 and gave the company an “overweight” rating in a research report on Tuesday, May 20th. JMP Securities lifted their price target on shares of American Healthcare REIT from $40.00 to $45.00 and gave the company a “market outperform” rating in a research report on Monday, August 11th. Robert W. Baird started coverage on shares of American Healthcare REIT in a research report on Friday, July 18th. They set an “outperform” rating and a $41.00 price target on the stock. KeyCorp boosted their target price on American Healthcare REIT from $34.00 to $40.00 and gave the company an “overweight” rating in a research report on Wednesday, June 11th. Finally, Baird R W raised American Healthcare REIT to a “strong-buy” rating in a research report on Thursday, July 17th. One investment analyst has rated the stock with a Strong Buy rating and ten have given a Buy rating to the stock. According to data from MarketBeat.com, American Healthcare REIT presently has a consensus rating of “Buy” and a consensus price target of $41.89.

Check Out Our Latest Stock Report on AHR

American Healthcare REIT Company Profile

(Free Report)

Formed by the successful merger of Griffin-American Healthcare REIT III and Griffin-American Healthcare REIT IV, as well as the acquisition of the business and operations of American Healthcare Investors, American Healthcare REIT is one of the larger healthcare-focused real estate investment trusts globally with assets totaling approximately $4.2 billion in gross investment value.

Further Reading

Want to see what other hedge funds are holding AHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for American Healthcare REIT, Inc. (NYSE:AHR – Free Report).

Receive News & Ratings for American Healthcare REIT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Healthcare REIT and related companies with MarketBeat.com's FREE daily email newsletter.
[Source link]: https://www.etfdailynews.com/2025/09/01/metlife-investment-management-llc-decreases-stock-holdings-in-american-healthcare-reit-inc-ahr/


[TITLE]Quantbot Technologies LP Makes New Investment in National HealthCare Co. $NHC:
[TEXT]
Quantbot Technologies LP bought a new stake in National HealthCare Co. (NYSE:NHC – Free Report) during the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm bought 2,987 shares of the company’s stock, valued at approximately $277,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Northern Trust Corp boosted its position in shares of National HealthCare by 4.8% during the 4th quarter. Northern Trust Corp now owns 193,792 shares of the company’s stock worth $20,844,000 after acquiring an additional 8,795 shares in the last quarter. Alps Advisors Inc. lifted its stake in National HealthCare by 7.7% during the first quarter. Alps Advisors Inc. now owns 147,800 shares of the company’s stock worth $13,716,000 after purchasing an additional 10,614 shares during the last quarter. Systematic Financial Management LP lifted its stake in National HealthCare by 3.5% during the fourth quarter. Systematic Financial Management LP now owns 117,884 shares of the company’s stock worth $12,680,000 after purchasing an additional 3,962 shares during the last quarter. Principal Financial Group Inc. boosted its holdings in shares of National HealthCare by 2.6% in the 1st quarter. Principal Financial Group Inc. now owns 65,410 shares of the company’s stock valued at $6,070,000 after purchasing an additional 1,671 shares in the last quarter. Finally, First Trust Advisors LP increased its stake in shares of National HealthCare by 75.6% in the 4th quarter. First Trust Advisors LP now owns 47,062 shares of the company’s stock valued at $5,062,000 after purchasing an additional 20,268 shares during the last quarter. Institutional investors own 56.44% of the company’s stock.

Get National HealthCare alerts:

Analysts Set New Price Targets

Separately, Wall Street Zen upgraded National HealthCare from a “buy” rating to a “strong-buy” rating in a research note on Monday, May 12th.

National HealthCare Stock Up 0.5%

Shares of NYSE:NHC opened at $111.97 on Thursday. National HealthCare Co. has a 52-week low of $89.14 and a 52-week high of $137.53. The company has a market capitalization of $1.74 billion, a PE ratio of 14.03 and a beta of 0.58. The company has a debt-to-equity ratio of 0.14, a quick ratio of 1.77 and a current ratio of 1.80. The company has a fifty day moving average of $103.37 and a 200-day moving average of $99.37.

National HealthCare Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be issued a $0.64 dividend. This represents a $2.56 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date of this dividend is Tuesday, September 30th. National HealthCare’s dividend payout ratio is presently 38.15%.

About National HealthCare

(Free Report)

National HealthCare Corporation engages in the operation of services to skilled nursing facilities, assisted and independent living facilities, homecare and hospice agencies, and health hospitals. Its skilled nursing facilities offer licensed therapy services, nutrition services, social services, activities, and housekeeping and laundry services, as well as medical services prescribed by physicians; and rehabilitative services, such as physical, speech, respiratory, and occupational therapy for patients recovering from strokes, heart attacks, orthopedic conditions, neurological illnesses, or other illnesses, injuries, or disabilities.

See Also

Want to see what other hedge funds are holding NHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for National HealthCare Co. (NYSE:NHC – Free Report).

Receive News & Ratings for National HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for National HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.
[Source link]: https://www.etfdailynews.com/2025/08/28/quantbot-technologies-lp-makes-new-investment-in-national-healthcare-co-nhc/

================================================================================

[TITLE]MetLife Investment Management LLC Decreases Stock Holdings in American Healthcare REIT, Inc. $AHR:
[TEXT]
MetLife Investment Management LLC trimmed its holdings in American Healthcare REIT, Inc. (NYSE:AHR – Free Report) by 1.6% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 94,449 shares of the company’s stock after selling 1,507 shares during the quarter. MetLife Investment Management LLC’s holdings in American Healthcare REIT were worth $2,862,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Wolff Wiese Magana LLC purchased a new stake in shares of American Healthcare REIT during the 1st quarter valued at approximately $25,000. MassMutual Private Wealth & Trust FSB raised its position in shares of American Healthcare REIT by 189.0% during the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 968 shares of the company’s stock valued at $29,000 after buying an additional 633 shares during the period. Spirit of America Management Corp NY purchased a new stake in shares of American Healthcare REIT during the 1st quarter valued at approximately $30,000. Avalon Trust Co purchased a new stake in shares of American Healthcare REIT during the 1st quarter valued at approximately $36,000. Finally, Continuum Advisory LLC purchased a new stake in shares of American Healthcare REIT during the 1st quarter valued at approximately $37,000. Hedge funds and other institutional investors own 16.68% of the company’s stock.

Get American Healthcare REIT alerts:

Insider Buying and Selling at American Healthcare REIT

In other news, CIO Stefan K.L. Oh sold 3,860 shares of the company’s stock in a transaction on Monday, June 30th. The stock was sold at an average price of $36.10, for a total transaction of $139,346.00. Following the sale, the executive owned 95,671 shares of the company’s stock, valued at approximately $3,453,723.10. This represents a 3.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 1.00% of the company’s stock.

American Healthcare REIT Stock Performance

NYSE:AHR opened at $42.79 on Monday. American Healthcare REIT, Inc. has a 52 week low of $20.15 and a 52 week high of $43.14. The company has a fifty day simple moving average of $38.75 and a two-hundred day simple moving average of $34.08. The company has a quick ratio of 0.48, a current ratio of 0.48 and a debt-to-equity ratio of 0.41. The company has a market cap of $7.21 billion, a price-to-earnings ratio of -194.48, a price-to-earnings-growth ratio of 2.19 and a beta of 1.09.

American Healthcare REIT (NYSE:AHR – Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported $0.42 earnings per share for the quarter, topping analysts’ consensus estimates of $0.40 by $0.02. American Healthcare REIT had a negative return on equity of 1.43% and a negative net margin of 1.56%.The business had revenue of $542.50 million for the quarter, compared to analyst estimates of $539.49 million. During the same quarter in the prior year, the company earned $0.33 earnings per share. The company’s revenue was up 7.5% on a year-over-year basis. American Healthcare REIT has set its FY 2025 guidance at 1.640-1.680 EPS. As a group, equities analysts anticipate that American Healthcare REIT, Inc. will post 1.41 earnings per share for the current fiscal year.

American Healthcare REIT Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, July 18th. Stockholders of record on Monday, June 30th were given a dividend of $0.25 per share. The ex-dividend date of this dividend was Monday, June 30th. This represents a $1.00 dividend on an annualized basis and a dividend yield of 2.3%. American Healthcare REIT’s dividend payout ratio is currently -454.55%.

Wall Street Analyst Weigh In

Several research firms have recently commented on AHR. Morgan Stanley lifted their price target on shares of American Healthcare REIT from $37.00 to $45.00 and gave the company an “overweight” rating in a research report on Tuesday, May 20th. JMP Securities lifted their price target on shares of American Healthcare REIT from $40.00 to $45.00 and gave the company a “market outperform” rating in a research report on Monday, August 11th. Robert W. Baird started coverage on shares of American Healthcare REIT in a research report on Friday, July 18th. They set an “outperform” rating and a $41.00 price target on the stock. KeyCorp boosted their target price on American Healthcare REIT from $34.00 to $40.00 and gave the company an “overweight” rating in a research report on Wednesday, June 11th. Finally, Baird R W raised American Healthcare REIT to a “strong-buy” rating in a research report on Thursday, July 17th. One investment analyst has rated the stock with a Strong Buy rating and ten have given a Buy rating to the stock. According to data from MarketBeat.com, American Healthcare REIT presently has a consensus rating of “Buy” and a consensus price target of $41.89.

Check Out Our Latest Stock Report on AHR

American Healthcare REIT Company Profile

(Free Report)

Formed by the successful merger of Griffin-American Healthcare REIT III and Griffin-American Healthcare REIT IV, as well as the acquisition of the business and operations of American Healthcare Investors, American Healthcare REIT is one of the larger healthcare-focused real estate investment trusts globally with assets totaling approximately $4.2 billion in gross investment value.

Further Reading

Want to see what other hedge funds are holding AHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for American Healthcare REIT, Inc. (NYSE:AHR – Free Report).

Receive News & Ratings for American Healthcare REIT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Healthcare REIT and related companies with MarketBeat.com's FREE daily email newsletter.
[Source link]: https://www.etfdailynews.com/2025/09/01/metlife-investment-management-llc-decreases-stock-holdings-in-american-healthcare-reit-inc-ahr/


[TITLE]Kestra Advisory Services LLC Acquires 11,077 Shares of GE HealthCare Technologies Inc. $GEHC:
[TEXT]
Kestra Advisory Services LLC raised its holdings in GE HealthCare Technologies Inc. (NASDAQ:GEHC – Free Report) by 74.1% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 26,028 shares of the company’s stock after purchasing an additional 11,077 shares during the quarter. Kestra Advisory Services LLC’s holdings in GE HealthCare Technologies were worth $2,101,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently bought and sold shares of the business. Knuff & Co LLC grew its stake in GE HealthCare Technologies by 1.5% in the 1st quarter. Knuff & Co LLC now owns 10,276 shares of the company’s stock valued at $829,000 after purchasing an additional 150 shares during the period. Graypoint LLC grew its stake in GE HealthCare Technologies by 5.7% in the 1st quarter. Graypoint LLC now owns 3,028 shares of the company’s stock valued at $244,000 after purchasing an additional 162 shares during the period. Ferguson Wellman Capital Management Inc. grew its stake in GE HealthCare Technologies by 3.2% in the 1st quarter. Ferguson Wellman Capital Management Inc. now owns 5,336 shares of the company’s stock valued at $431,000 after purchasing an additional 166 shares during the period. Spire Wealth Management grew its stake in GE HealthCare Technologies by 5.2% in the 1st quarter. Spire Wealth Management now owns 3,367 shares of the company’s stock valued at $272,000 after purchasing an additional 166 shares during the period. Finally, Freestone Capital Holdings LLC lifted its position in shares of GE HealthCare Technologies by 5.1% during the 1st quarter. Freestone Capital Holdings LLC now owns 3,454 shares of the company’s stock valued at $279,000 after buying an additional 169 shares during the last quarter. Institutional investors own 82.06% of the company’s stock.

Get GE HealthCare Technologies alerts:

Analysts Set New Price Targets

A number of brokerages have recently commented on GEHC. BTIG Research reaffirmed a “buy” rating on shares of GE HealthCare Technologies in a research report on Monday, July 14th. UBS Group raised GE HealthCare Technologies from a “sell” rating to a “neutral” rating and dropped their price target for the company from $74.00 to $73.00 in a research report on Monday, May 5th. Citigroup upped their price target on GE HealthCare Technologies from $89.00 to $93.00 and gave the company a “buy” rating in a research report on Thursday, July 31st. Morgan Stanley dropped their price target on GE HealthCare Technologies from $78.00 to $74.00 and set an “equal weight” rating on the stock in a research report on Thursday, July 31st. Finally, Wall Street Zen raised GE HealthCare Technologies from a “hold” rating to a “buy” rating in a research report on Saturday, May 31st. Eight equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $88.55.

GE HealthCare Technologies Stock Performance

Shares of GEHC opened at $73.73 on Friday. The stock’s 50-day simple moving average is $74.23 and its 200 day simple moving average is $74.76. The stock has a market capitalization of $33.66 billion, a price-to-earnings ratio of 15.11, a price-to-earnings-growth ratio of 2.82 and a beta of 1.13. The company has a debt-to-equity ratio of 0.85, a quick ratio of 0.93 and a current ratio of 1.16. GE HealthCare Technologies Inc. has a 52-week low of $57.65 and a 52-week high of $94.80.

GE HealthCare Technologies (NASDAQ:GEHC – Get Free Report) last issued its quarterly earnings data on Wednesday, July 30th. The company reported $1.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.91 by $0.15. GE HealthCare Technologies had a return on equity of 23.93% and a net margin of 11.22%.The business had revenue of $5 billion for the quarter, compared to analysts’ expectations of $4.96 billion. During the same quarter in the prior year, the firm posted $1.00 EPS. The firm’s quarterly revenue was up 3.5% on a year-over-year basis. GE HealthCare Technologies has set its FY 2025 guidance at 4.430-4.630 EPS. Research analysts forecast that GE HealthCare Technologies Inc. will post 4.68 EPS for the current fiscal year.

GE HealthCare Technologies Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, August 15th. Shareholders of record on Friday, July 25th were issued a $0.035 dividend. The ex-dividend date of this dividend was Friday, July 25th. This represents a $0.14 annualized dividend and a dividend yield of 0.2%. GE HealthCare Technologies’s dividend payout ratio (DPR) is presently 2.87%.

GE HealthCare Technologies Profile

(Free Report)

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.

Further Reading

Want to see what other hedge funds are holding GEHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GE HealthCare Technologies Inc. (NASDAQ:GEHC – Free Report).

Receive News & Ratings for GE HealthCare Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GE HealthCare Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
[Source link]: https://www.etfdailynews.com/2025/08/30/kestra-advisory-services-llc-acquires-11077-shares-of-ge-healthcare-technologies-inc-gehc/


[TITLE]Vesper Healthcare Acquisition (OTCMKTS:VSPRU) Trading Down 2.2% – Time to Sell?:
[TEXT]
Vesper Healthcare Acquisition Corp. (OTCMKTS:VSPRU – Get Free Report)’s share price fell 2.2% during mid-day trading on Friday . The stock traded as low as $13.83 and last traded at $14.00. 4,200 shares traded hands during trading, a decline of 83% from the average session volume of 24,185 shares. The stock had previously closed at $14.31.

Vesper Healthcare Acquisition Trading Down 2.2%

The company’s fifty day moving average is $14.00 and its 200-day moving average is $14.00.
[Source link]: https://www.etfdailynews.com/2025/08/30/vesper-healthcare-acquisition-otcmktsvspru-trading-down-2-2-time-to-sell/


[TITLE]Quantbot Technologies LP Makes New Investment in National HealthCare Co. $NHC:
[TEXT]
Quantbot Technologies LP bought a new stake in National HealthCare Co. (NYSE:NHC – Free Report) during the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm bought 2,987 shares of the company’s stock, valued at approximately $277,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Northern Trust Corp boosted its position in shares of National HealthCare by 4.8% during the 4th quarter. Northern Trust Corp now owns 193,792 shares of the company’s stock worth $20,844,000 after acquiring an additional 8,795 shares in the last quarter. Alps Advisors Inc. lifted its stake in National HealthCare by 7.7% during the first quarter. Alps Advisors Inc. now owns 147,800 shares of the company’s stock worth $13,716,000 after purchasing an additional 10,614 shares during the last quarter. Systematic Financial Management LP lifted its stake in National HealthCare by 3.5% during the fourth quarter. Systematic Financial Management LP now owns 117,884 shares of the company’s stock worth $12,680,000 after purchasing an additional 3,962 shares during the last quarter. Principal Financial Group Inc. boosted its holdings in shares of National HealthCare by 2.6% in the 1st quarter. Principal Financial Group Inc. now owns 65,410 shares of the company’s stock valued at $6,070,000 after purchasing an additional 1,671 shares in the last quarter. Finally, First Trust Advisors LP increased its stake in shares of National HealthCare by 75.6% in the 4th quarter. First Trust Advisors LP now owns 47,062 shares of the company’s stock valued at $5,062,000 after purchasing an additional 20,268 shares during the last quarter. Institutional investors own 56.44% of the company’s stock.

Get National HealthCare alerts:

Analysts Set New Price Targets

Separately, Wall Street Zen upgraded National HealthCare from a “buy” rating to a “strong-buy” rating in a research note on Monday, May 12th.

National HealthCare Stock Up 0.5%

Shares of NYSE:NHC opened at $111.97 on Thursday. National HealthCare Co. has a 52-week low of $89.14 and a 52-week high of $137.53. The company has a market capitalization of $1.74 billion, a PE ratio of 14.03 and a beta of 0.58. The company has a debt-to-equity ratio of 0.14, a quick ratio of 1.77 and a current ratio of 1.80. The company has a fifty day moving average of $103.37 and a 200-day moving average of $99.37.

National HealthCare Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be issued a $0.64 dividend. This represents a $2.56 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date of this dividend is Tuesday, September 30th. National HealthCare’s dividend payout ratio is presently 38.15%.

About National HealthCare

(Free Report)

National HealthCare Corporation engages in the operation of services to skilled nursing facilities, assisted and independent living facilities, homecare and hospice agencies, and health hospitals. Its skilled nursing facilities offer licensed therapy services, nutrition services, social services, activities, and housekeeping and laundry services, as well as medical services prescribed by physicians; and rehabilitative services, such as physical, speech, respiratory, and occupational therapy for patients recovering from strokes, heart attacks, orthopedic conditions, neurological illnesses, or other illnesses, injuries, or disabilities.

See Also

Want to see what other hedge funds are holding NHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for National HealthCare Co. (NYSE:NHC – Free Report).

Receive News & Ratings for National HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for National HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.
[Source link]: https://www.etfdailynews.com/2025/08/28/quantbot-technologies-lp-makes-new-investment-in-national-healthcare-co-nhc/

================================================================================

[TITLE]Raymond James Financial Inc. Increases Stake in ARS Pharmaceuticals, Inc. $SPRY:
[TEXT]
Raymond James Financial Inc. boosted its position in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Free Report) by 13.4% during the 1st quarter, HoldingsChannel.com reports. The firm owned 706,787 shares of the company’s stock after purchasing an additional 83,506 shares during the period. Raymond James Financial Inc.’s holdings in ARS Pharmaceuticals were worth $8,891,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Aberdeen Group plc bought a new stake in ARS Pharmaceuticals in the 1st quarter worth
[Source link]: https://www.etfdailynews.com/2025/09/01/raymond-james-financial-inc-increases-stake-in-ars-pharmaceuticals-inc-spry/


[TITLE]Avadel Pharmaceuticals PLC. $AVDL Shares Bought by Charles Schwab Investment Management Inc.:
[TEXT]
Charles Schwab Investment Management Inc. increased its stake in Avadel Pharmaceuticals PLC. (NASDAQ:AVDL – Free Report) by 1.6% in the first quarter, Holdings Channel.com reports. The institutional investor owned 226,439 shares of the company’s stock after purchasing an additional 3,641 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Avadel Pharmaceuticals were worth $1,773,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of AVDL. Invesco Ltd. boosted its stake in shares of Avadel Pharmaceuticals by 2.3% in the fourth quarter. Invesco Ltd. now owns 52,142 shares of the company’s stock valued at $548,000 after purchasing an additional 1,177 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Avadel Pharmaceuticals by 3.7% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 52,594 shares of the company’s stock worth $553,000 after buying an additional 1,882 shares in the last quarter. Rhumbline Advisers lifted its holdings in Avadel Pharmaceuticals by 2.3% in the 1st quarter. Rhumbline Advisers now owns 127,027 shares of the company’s stock worth $995,000 after buying an additional 2,890 shares in the last quarter. MetLife Investment Management LLC boosted its position in Avadel Pharmaceuticals by 6.1% in the 4th quarter. MetLife Investment Management LLC now owns 57,068 shares of the company’s stock valued at $600,000 after buying an additional 3,271 shares during the last quarter. Finally, Edge Wealth Management LLC grew its stake in shares of Avadel Pharmaceuticals by 25.0% during the first quarter. Edge Wealth Management LLC now owns 25,000 shares of the company’s stock valued at $196,000 after acquiring an additional 5,000 shares in the last quarter. 69.19% of the stock is currently owned by hedge funds and other institutional investors.

Get Avadel Pharmaceuticals alerts:

Avadel Pharmaceuticals Trading Up 1.0%

Shares of NASDAQ AVDL opened at $14.76 on Monday. Avadel Pharmaceuticals PLC. has a twelve month low of $6.38 and a twelve month high of $16.66. The company has a market capitalization of $1.43 billion, a price-to-earnings ratio of -492.00 and a beta of 1.57. The business has a 50 day simple moving average of $11.44 and a 200-day simple moving average of $9.53.

Analyst Upgrades and Downgrades

Avadel Pharmaceuticals ( NASDAQ:AVDL Get Free Report ) last announced its quarterly earnings data on Thursday, August 7th. The company reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.02 by $0.08. The firm had revenue of $68.13 million for the quarter, compared to analysts’ expectations of $60.28 million. Avadel Pharmaceuticals had a negative return on equity of 3.73% and a negative net margin of 1.32%.The firm’s revenue for the quarter was up 64.1% on a year-over-year basis. During the same period last year, the business posted ($0.14) earnings per share. Avadel Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, equities analysts predict that Avadel Pharmaceuticals PLC. will post -0.51 earnings per share for the current year.

Several research analysts recently commented on the company. Wall Street Zen upgraded Avadel Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 9th. Zacks Research upgraded Avadel Pharmaceuticals to a “strong-buy” rating in a report on Friday, August 8th. HC Wainwright reaffirmed a “buy” rating and issued a $24.00 target price (up from $22.00) on shares of Avadel Pharmaceuticals in a research report on Friday, August 8th. Needham & Company LLC reissued a “buy” rating and set a $19.00 price target on shares of Avadel Pharmaceuticals in a research report on Thursday, May 8th. Finally, UBS Group lifted their price target on shares of Avadel Pharmaceuticals from $13.00 to $20.00 and gave the stock a “buy” rating in a research note on Thursday, August 21st. One investment analyst has rated the stock with a Strong Buy rating and six have issued a Buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $19.67.

View Our Latest Stock Report on AVDL

About Avadel Pharmaceuticals

(Free Report)

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.

Further Reading

Want to see what other hedge funds are holding AVDL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Avadel Pharmaceuticals PLC. (NASDAQ:AVDL – Free Report).

Receive News & Ratings for Avadel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avadel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
[Source link]: https://www.etfdailynews.com/2025/09/01/avadel-pharmaceuticals-plc-avdl-shares-bought-by-charles-schwab-investment-management-inc/


[TITLE]Wellington Management Group LLP Acquires 23,660 Shares of Centessa Pharmaceuticals PLC Sponsored ADR $CNTA:
[TEXT]
Wellington Management Group LLP boosted its position in Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA – Free Report) by 20.6% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 138,767 shares of the company’s stock after buying an additional 23,660 shares during the period. Wellington Management Group LLP’s holdings in Centessa Pharmaceuticals were worth $1,995,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. GF Fund Management CO. LTD. bought a new stake in Centessa Pharmaceuticals in the 4th quarter valued at
[Source link]: https://www.etfdailynews.com/2025/08/31/wellington-management-group-llp-acquires-23660-shares-of-centessa-pharmaceuticals-plc-sponsored-adr-cnta/


[TITLE]Quantbot Technologies LP Makes New Investment in Eton Pharmaceuticals, Inc. $ETON:
[TEXT]
Quantbot Technologies LP acquired a new position in shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON – Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 7,794 shares of the company’s stock, valued at approximately $101,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in ETON. Mink Brook Asset Management LLC acquired a new stake in Eton Pharmaceuticals during the fourth quarter worth approximately $6,071,000. Millennium Management LLC acquired a new stake in Eton Pharmaceuticals during the fourth quarter worth approximately $1,850,000. Two Sigma Investments LP acquired a new stake in Eton Pharmaceuticals during the fourth quarter worth approximately $1,498,000. Schonfeld Strategic Advisors LLC raised its holdings in Eton Pharmaceuticals by 421.3% during the fourth quarter. Schonfeld Strategic Advisors LLC now owns 89,664 shares of the company’s stock worth $1,194,000 after purchasing an additional 72,464 shares in the last quarter. Finally, 683 Capital Management LLC acquired a new stake in Eton Pharmaceuticals during the fourth quarter worth approximately $919,000. Institutional investors and hedge funds own 27.86% of the company’s stock.

Get Eton Pharmaceuticals alerts:

Insiders Place Their Bets

In related news, CFO James R. Gruber sold 39,082 shares of Eton Pharmaceuticals stock in a transaction on Tuesday, August 19th. The shares were sold at an average price of $16.16, for a total value of $631,565.12. Following the transaction, the chief financial officer directly owned 205,299 shares in the company, valued at $3,317,631.84. This trade represents a 15.99% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider David Krempa sold 16,977 shares of Eton Pharmaceuticals stock in a transaction on Thursday, June 12th. The shares were sold at an average price of $14.92, for a total transaction of $253,296.84. Following the completion of the transaction, the insider owned 629,669 shares in the company, valued at approximately $9,394,661.48. This trade represents a 2.63% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 75,713 shares of company stock worth $1,178,031. 16.03% of the stock is currently owned by insiders.

Eton Pharmaceuticals Stock Performance

Shares of Eton Pharmaceuticals stock opened at $17.31 on Friday. The firm’s fifty day simple moving average is $15.35 and its 200-day simple moving average is $15.45. The stock has a market capitalization of $464.25 million, a price-to-earnings ratio of -108.19 and a beta of 1.13. Eton Pharmaceuticals, Inc. has a 12 month low of $4.47 and a 12 month high of $21.48. The company has a debt-to-equity ratio of 1.14, a current ratio of 1.77 and a quick ratio of 1.16.

Eton Pharmaceuticals (NASDAQ:ETON – Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.09). Eton Pharmaceuticals had a negative net margin of 7.10% and a negative return on equity of 0.73%. The firm had revenue of $18.93 million during the quarter, compared to analysts’ expectations of $16.71 million. As a group, equities analysts forecast that Eton Pharmaceuticals, Inc. will post -0.14 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have weighed in on ETON. Wall Street Zen cut shares of Eton Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, August 9th. Craig Hallum raised their price objective on shares of Eton Pharmaceuticals from $26.00 to $28.00 and gave the stock a “buy” rating in a report on Wednesday, May 14th. B. Riley reaffirmed a “buy” rating and issued a $26.00 target price (up from $24.00) on shares of Eton Pharmaceuticals in a report on Friday, May 16th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $35.00 target price (up from $33.00) on shares of Eton Pharmaceuticals in a report on Thursday, May 29th. Three research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Eton Pharmaceuticals has an average rating of “Buy” and a consensus target price of $29.67.

Check Out Our Latest Stock Report on ETON

Eton Pharmaceuticals Profile

(Free Report)

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.

See Also

Receive News & Ratings for Eton Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eton Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
[Source link]: https://www.etfdailynews.com/2025/08/30/quantbot-technologies-lp-makes-new-investment-in-eton-pharmaceuticals-inc-eton/

================================================================================

[TITLE]Sana Biotechnology, Inc. $SANA Shares Purchased by Charles Schwab Investment Management Inc.:
[TEXT]
Charles Schwab Investment Management Inc. boosted its position in Sana Biotechnology, Inc. (NASDAQ:SANA – Free Report) by 0.9% in the 1st quarter, Holdings Channel reports. The firm owned 1,066,304 shares of the company’s stock after acquiring an additional 9,792 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Sana Biotechnology were worth $1,791,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Sana Biotechnology by 2.4% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 280,731 shares of the company’s stock worth $457,000 after buying an additional 6,613 shares in the last quarter. Bank of New York Mellon Corp boosted its position in Sana Biotechnology by 2.1% during the first quarter. Bank of New York Mellon Corp now owns 344,058 shares of the company’s stock worth $578,000 after acquiring an additional 7,230 shares during the last quarter. Rhumbline Advisers grew its stake in Sana Biotechnology by 5.4% during the 1st quarter. Rhumbline Advisers now owns 182,134 shares of the company’s stock valued at $306,000 after acquiring an additional 9,359 shares in the last quarter. ProShare Advisors LLC raised its holdings in Sana Biotechnology by 25.4% in the 4th quarter. ProShare Advisors LLC now owns 47,808 shares of the company’s stock valued at $78,000 after acquiring an additional 9,679 shares during the last quarter. Finally, Tower Research Capital LLC TRC raised its holdings in Sana Biotechnology by 229.9% in the 4th quarter. Tower Research Capital LLC TRC now owns 15,136 shares of the company’s stock valued at $25,000 after acquiring an additional 10,548 shares during the last quarter. Institutional investors and hedge funds own 88.23% of the company’s stock.

Get Sana Biotechnology alerts:

Sana Biotechnology Trading Up 1.7%

Shares of SANA opened at $3.06 on Monday. The company’s 50-day moving average price is $3.69 and its 200 day moving average price is $2.70. Sana Biotechnology, Inc. has a 12-month low of $1.26 and a 12-month high of $7.30. The firm has a market cap of $727.70 million, a P/E ratio of -2.89 and a beta of 1.88.

Analysts Set New Price Targets

Sana Biotechnology ( NASDAQ:SANA Get Free Report ) last announced its earnings results on Monday, August 11th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.04. Equities research analysts forecast that Sana Biotechnology, Inc. will post -1.16 earnings per share for the current year.

Several research analysts have recently weighed in on SANA shares. JMP Securities restated a “market outperform” rating and set a $5.00 target price on shares of Sana Biotechnology in a report on Tuesday, June 24th. Morgan Stanley assumed coverage on Sana Biotechnology in a research note on Thursday, July 3rd. They set an “overweight” rating and a $12.00 price objective on the stock. Six analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $8.00.

Read Our Latest Report on Sana Biotechnology

Sana Biotechnology Company Profile

(Free Report)

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.

Further Reading

Want to see what other hedge funds are holding SANA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sana Biotechnology, Inc. (NASDAQ:SANA – Free Report).

Receive News & Ratings for Sana Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sana Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
[Source link]: https://www.etfdailynews.com/2025/09/01/sana-biotechnology-inc-sana-shares-purchased-by-charles-schwab-investment-management-inc/


[Failed to load article at https://www.psychologytoday.com/us/blog/mental-health-today/202508/global-healthcare-stakeholders-call-increased-investment-mental-health-services]


[Failed to load article at https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treat-rare-genetic-disorder]


[Failed to load article at https://www.healthcareitnews.com/news/healthcare-industry-leaders-discuss-future-trends-telemedicine-and-remote-patient-monitoring]

================================================================================

[TITLE]University of Hyderabad joins global collaboration to tackle single-use plastics in healthcare:
[TEXT]
The Department of Anthropology at the University of Hyderabad will be participating in an international project aimed at addressing the environmental and health impacts of single-use plastics in healthcare.

The “After the Single Use” project, funded by the Wellcome Trust with a £5.9 million Discovery Award, brings together a global team of researchers from eight countries to explore the cultural, social, and environmental dimensions of medical plastics and promote circular healthcare economies.

Led by Nanda Kishore Kannuri, Associate Professor in the Department of Anthropology, UoH, will receive a grant of £422,608 (approximately ₹5 crore) over a five-year period to contribute to this significant initiative.

The project will examine the historical, local, and global factors that have shaped the current healthcare waste crisis, analyze the life cycles of disposable medical technologies, and collaborate with policymakers, activists, engineers, and designers to develop sustainable solutions.

“This collaboration represents a significant opportunity for the University of Hyderabad to contribute to a global initiative at the intersection of anthropology, environmental sustainability, and healthcare,” Nanda Kishore Kannuri.

“We look forward to working with our international partners to develop innovative solutions that can be applied in diverse healthcare settings,’‘ he added.

The “After the Single Use” project involves a global team of collaborators from the University of Edinburgh (UK), University of New South Wales (Australia), University of Geneva (Switzerland), University of Oslo (Norway), National Institute of Medical Research (Tanzania), CRCF (Senegal), PNG Institute of Medical Research (Papua New Guinea), and Johns Hopkins University (USA), as well as key NGO partners Health Care Without Harm and the Norwegian Bioart Arena.

Published on September 1, 2025
[Source link]: https://www.thehindubusinessline.com/news/education/university-of-hyderabad-joins-global-collaboration-to-tackle-single-use-plastics-in-healthcare/article69999995.ece


[TITLE]MetLife Investment Management LLC Decreases Stock Holdings in American Healthcare REIT, Inc. $AHR:
[TEXT]
MetLife Investment Management LLC trimmed its holdings in American Healthcare REIT, Inc. (NYSE:AHR – Free Report) by 1.6% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 94,449 shares of the company’s stock after selling 1,507 shares during the quarter. MetLife Investment Management LLC’s holdings in American Healthcare REIT were worth $2,862,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Wolff Wiese Magana LLC purchased a new stake in shares of American Healthcare REIT during the 1st quarter valued at approximately $25,000. MassMutual Private Wealth & Trust FSB raised its position in shares of American Healthcare REIT by 189.0% during the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 968 shares of the company’s stock valued at $29,000 after buying an additional 633 shares during the period. Spirit of America Management Corp NY purchased a new stake in shares of American Healthcare REIT during the 1st quarter valued at approximately $30,000. Avalon Trust Co purchased a new stake in shares of American Healthcare REIT during the 1st quarter valued at approximately $36,000. Finally, Continuum Advisory LLC purchased a new stake in shares of American Healthcare REIT during the 1st quarter valued at approximately $37,000. Hedge funds and other institutional investors own 16.68% of the company’s stock.

Get American Healthcare REIT alerts:

Insider Buying and Selling at American Healthcare REIT

In other news, CIO Stefan K.L. Oh sold 3,860 shares of the company’s stock in a transaction on Monday, June 30th. The stock was sold at an average price of $36.10, for a total transaction of $139,346.00. Following the sale, the executive owned 95,671 shares of the company’s stock, valued at approximately $3,453,723.10. This represents a 3.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 1.00% of the company’s stock.

American Healthcare REIT Stock Performance

NYSE:AHR opened at $42.79 on Monday. American Healthcare REIT, Inc. has a 52 week low of $20.15 and a 52 week high of $43.14. The company has a fifty day simple moving average of $38.75 and a two-hundred day simple moving average of $34.08. The company has a quick ratio of 0.48, a current ratio of 0.48 and a debt-to-equity ratio of 0.41. The company has a market cap of $7.21 billion, a price-to-earnings ratio of -194.48, a price-to-earnings-growth ratio of 2.19 and a beta of 1.09.

American Healthcare REIT (NYSE:AHR – Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported $0.42 earnings per share for the quarter, topping analysts’ consensus estimates of $0.40 by $0.02. American Healthcare REIT had a negative return on equity of 1.43% and a negative net margin of 1.56%.The business had revenue of $542.50 million for the quarter, compared to analyst estimates of $539.49 million. During the same quarter in the prior year, the company earned $0.33 earnings per share. The company’s revenue was up 7.5% on a year-over-year basis. American Healthcare REIT has set its FY 2025 guidance at 1.640-1.680 EPS. As a group, equities analysts anticipate that American Healthcare REIT, Inc. will post 1.41 earnings per share for the current fiscal year.

American Healthcare REIT Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, July 18th. Stockholders of record on Monday, June 30th were given a dividend of $0.25 per share. The ex-dividend date of this dividend was Monday, June 30th. This represents a $1.00 dividend on an annualized basis and a dividend yield of 2.3%. American Healthcare REIT’s dividend payout ratio is currently -454.55%.

Wall Street Analyst Weigh In

Several research firms have recently commented on AHR. Morgan Stanley lifted their price target on shares of American Healthcare REIT from $37.00 to $45.00 and gave the company an “overweight” rating in a research report on Tuesday, May 20th. JMP Securities lifted their price target on shares of American Healthcare REIT from $40.00 to $45.00 and gave the company a “market outperform” rating in a research report on Monday, August 11th. Robert W. Baird started coverage on shares of American Healthcare REIT in a research report on Friday, July 18th. They set an “outperform” rating and a $41.00 price target on the stock. KeyCorp boosted their target price on American Healthcare REIT from $34.00 to $40.00 and gave the company an “overweight” rating in a research report on Wednesday, June 11th. Finally, Baird R W raised American Healthcare REIT to a “strong-buy” rating in a research report on Thursday, July 17th. One investment analyst has rated the stock with a Strong Buy rating and ten have given a Buy rating to the stock. According to data from MarketBeat.com, American Healthcare REIT presently has a consensus rating of “Buy” and a consensus price target of $41.89.

Check Out Our Latest Stock Report on AHR

American Healthcare REIT Company Profile

(Free Report)

Formed by the successful merger of Griffin-American Healthcare REIT III and Griffin-American Healthcare REIT IV, as well as the acquisition of the business and operations of American Healthcare Investors, American Healthcare REIT is one of the larger healthcare-focused real estate investment trusts globally with assets totaling approximately $4.2 billion in gross investment value.

Further Reading

Want to see what other hedge funds are holding AHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for American Healthcare REIT, Inc. (NYSE:AHR – Free Report).

Receive News & Ratings for American Healthcare REIT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Healthcare REIT and related companies with MarketBeat.com's FREE daily email newsletter.
[Source link]: https://www.etfdailynews.com/2025/09/01/metlife-investment-management-llc-decreases-stock-holdings-in-american-healthcare-reit-inc-ahr/


[TITLE]Kestra Advisory Services LLC Acquires 11,077 Shares of GE HealthCare Technologies Inc. $GEHC:
[TEXT]
Kestra Advisory Services LLC raised its holdings in GE HealthCare Technologies Inc. (NASDAQ:GEHC – Free Report) by 74.1% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 26,028 shares of the company’s stock after purchasing an additional 11,077 shares during the quarter. Kestra Advisory Services LLC’s holdings in GE HealthCare Technologies were worth $2,101,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently bought and sold shares of the business. Knuff & Co LLC grew its stake in GE HealthCare Technologies by 1.5% in the 1st quarter. Knuff & Co LLC now owns 10,276 shares of the company’s stock valued at $829,000 after purchasing an additional 150 shares during the period. Graypoint LLC grew its stake in GE HealthCare Technologies by 5.7% in the 1st quarter. Graypoint LLC now owns 3,028 shares of the company’s stock valued at $244,000 after purchasing an additional 162 shares during the period. Ferguson Wellman Capital Management Inc. grew its stake in GE HealthCare Technologies by 3.2% in the 1st quarter. Ferguson Wellman Capital Management Inc. now owns 5,336 shares of the company’s stock valued at $431,000 after purchasing an additional 166 shares during the period. Spire Wealth Management grew its stake in GE HealthCare Technologies by 5.2% in the 1st quarter. Spire Wealth Management now owns 3,367 shares of the company’s stock valued at $272,000 after purchasing an additional 166 shares during the period. Finally, Freestone Capital Holdings LLC lifted its position in shares of GE HealthCare Technologies by 5.1% during the 1st quarter. Freestone Capital Holdings LLC now owns 3,454 shares of the company’s stock valued at $279,000 after buying an additional 169 shares during the last quarter. Institutional investors own 82.06% of the company’s stock.

Get GE HealthCare Technologies alerts:

Analysts Set New Price Targets

A number of brokerages have recently commented on GEHC. BTIG Research reaffirmed a “buy” rating on shares of GE HealthCare Technologies in a research report on Monday, July 14th. UBS Group raised GE HealthCare Technologies from a “sell” rating to a “neutral” rating and dropped their price target for the company from $74.00 to $73.00 in a research report on Monday, May 5th. Citigroup upped their price target on GE HealthCare Technologies from $89.00 to $93.00 and gave the company a “buy” rating in a research report on Thursday, July 31st. Morgan Stanley dropped their price target on GE HealthCare Technologies from $78.00 to $74.00 and set an “equal weight” rating on the stock in a research report on Thursday, July 31st. Finally, Wall Street Zen raised GE HealthCare Technologies from a “hold” rating to a “buy” rating in a research report on Saturday, May 31st. Eight equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $88.55.

GE HealthCare Technologies Stock Performance

Shares of GEHC opened at $73.73 on Friday. The stock’s 50-day simple moving average is $74.23 and its 200 day simple moving average is $74.76. The stock has a market capitalization of $33.66 billion, a price-to-earnings ratio of 15.11, a price-to-earnings-growth ratio of 2.82 and a beta of 1.13. The company has a debt-to-equity ratio of 0.85, a quick ratio of 0.93 and a current ratio of 1.16. GE HealthCare Technologies Inc. has a 52-week low of $57.65 and a 52-week high of $94.80.

GE HealthCare Technologies (NASDAQ:GEHC – Get Free Report) last issued its quarterly earnings data on Wednesday, July 30th. The company reported $1.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.91 by $0.15. GE HealthCare Technologies had a return on equity of 23.93% and a net margin of 11.22%.The business had revenue of $5 billion for the quarter, compared to analysts’ expectations of $4.96 billion. During the same quarter in the prior year, the firm posted $1.00 EPS. The firm’s quarterly revenue was up 3.5% on a year-over-year basis. GE HealthCare Technologies has set its FY 2025 guidance at 4.430-4.630 EPS. Research analysts forecast that GE HealthCare Technologies Inc. will post 4.68 EPS for the current fiscal year.

GE HealthCare Technologies Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, August 15th. Shareholders of record on Friday, July 25th were issued a $0.035 dividend. The ex-dividend date of this dividend was Friday, July 25th. This represents a $0.14 annualized dividend and a dividend yield of 0.2%. GE HealthCare Technologies’s dividend payout ratio (DPR) is presently 2.87%.

GE HealthCare Technologies Profile

(Free Report)

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.

Further Reading

Want to see what other hedge funds are holding GEHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GE HealthCare Technologies Inc. (NASDAQ:GEHC – Free Report).

Receive News & Ratings for GE HealthCare Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GE HealthCare Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
[Source link]: https://www.etfdailynews.com/2025/08/30/kestra-advisory-services-llc-acquires-11077-shares-of-ge-healthcare-technologies-inc-gehc/


[TITLE]Quantbot Technologies LP Makes New Investment in National HealthCare Co. $NHC:
[TEXT]
Quantbot Technologies LP bought a new stake in National HealthCare Co. (NYSE:NHC – Free Report) during the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm bought 2,987 shares of the company’s stock, valued at approximately $277,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Northern Trust Corp boosted its position in shares of National HealthCare by 4.8% during the 4th quarter. Northern Trust Corp now owns 193,792 shares of the company’s stock worth $20,844,000 after acquiring an additional 8,795 shares in the last quarter. Alps Advisors Inc. lifted its stake in National HealthCare by 7.7% during the first quarter. Alps Advisors Inc. now owns 147,800 shares of the company’s stock worth $13,716,000 after purchasing an additional 10,614 shares during the last quarter. Systematic Financial Management LP lifted its stake in National HealthCare by 3.5% during the fourth quarter. Systematic Financial Management LP now owns 117,884 shares of the company’s stock worth $12,680,000 after purchasing an additional 3,962 shares during the last quarter. Principal Financial Group Inc. boosted its holdings in shares of National HealthCare by 2.6% in the 1st quarter. Principal Financial Group Inc. now owns 65,410 shares of the company’s stock valued at $6,070,000 after purchasing an additional 1,671 shares in the last quarter. Finally, First Trust Advisors LP increased its stake in shares of National HealthCare by 75.6% in the 4th quarter. First Trust Advisors LP now owns 47,062 shares of the company’s stock valued at $5,062,000 after purchasing an additional 20,268 shares during the last quarter. Institutional investors own 56.44% of the company’s stock.

Get National HealthCare alerts:

Analysts Set New Price Targets

Separately, Wall Street Zen upgraded National HealthCare from a “buy” rating to a “strong-buy” rating in a research note on Monday, May 12th.

National HealthCare Stock Up 0.5%

Shares of NYSE:NHC opened at $111.97 on Thursday. National HealthCare Co. has a 52-week low of $89.14 and a 52-week high of $137.53. The company has a market capitalization of $1.74 billion, a PE ratio of 14.03 and a beta of 0.58. The company has a debt-to-equity ratio of 0.14, a quick ratio of 1.77 and a current ratio of 1.80. The company has a fifty day moving average of $103.37 and a 200-day moving average of $99.37.

National HealthCare Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be issued a $0.64 dividend. This represents a $2.56 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date of this dividend is Tuesday, September 30th. National HealthCare’s dividend payout ratio is presently 38.15%.

About National HealthCare

(Free Report)

National HealthCare Corporation engages in the operation of services to skilled nursing facilities, assisted and independent living facilities, homecare and hospice agencies, and health hospitals. Its skilled nursing facilities offer licensed therapy services, nutrition services, social services, activities, and housekeeping and laundry services, as well as medical services prescribed by physicians; and rehabilitative services, such as physical, speech, respiratory, and occupational therapy for patients recovering from strokes, heart attacks, orthopedic conditions, neurological illnesses, or other illnesses, injuries, or disabilities.

See Also

Want to see what other hedge funds are holding NHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for National HealthCare Co. (NYSE:NHC – Free Report).

Receive News & Ratings for National HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for National HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.
[Source link]: https://www.etfdailynews.com/2025/08/28/quantbot-technologies-lp-makes-new-investment-in-national-healthcare-co-nhc/

================================================================================

